Phase 1 Study of a Recombinant Mutant Protective Antigen of Bacillus anthracis

A phase 1 study of a recombinant mutant protective antigen (rPA) vaccine was conducted in 186 healthy adults aged 18 to 45 years. Volunteers were randomized to receive one of three formulations of rPA (formalin treated, alum adsorbed, or both), in 10- or 20-μg dosages each, or the licensed vaccine,...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Bellanti, Joseph A., Lin, Feng-Ying C., Chu, Chiayung, Shiloach, Joseph, Leppla, Stephen H., Benavides, German A., Karpas, Arthur, Moayeri, Mahtab, Guo, Chunyan, Robbins, John B., Schneerson, Rachel
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Microbiology 2012
Konular:
Vaccines
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3272932/
https://ncbi.nlm.nih.gov/pubmed/22190398
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.05556-11
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller